Brief: Clover Appoints Nicholas Jackson, Ph.D., As President Of Global Research And Development
01/02/2022 14:14
Feb 1 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* CLOVER APPOINTS NICHOLAS JACKSON, PH.D., AS PRESIDENT OF
GLOBAL
RESEARCH AND DEVELOPMENT
Source text for Eikon: ID:nGNXc87ZrR
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune